Catalog Products » SLPI hFc Chimera, Human
Manual
Manual
COAs

SLPI hFc Chimera, Human

Elafin and SLPI (secretory leucocyte protease inhibitor) have multiple important roles both in normal homoeostasis and at sites of inflammation. These include antiprotease and antimicrobial activity as well as modulation of the response to LPS (lipopolysaccharide) stimulation. Elafin and SLPI are members of larger families of proteins secreted predominantly at mucosal sites, and have been shown to be modulated in multiple pathological conditions.
$300.00
Z05847-100

Ask us a question
Product Introduction
Species Human
Protein Construction
SLPI (Ser26-Ala132)_x000D_
Accession # P03973		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 38.5 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS, 350mM NaCl (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

SLPI HFc Chimera, Human

Immobilized SLPI hFc Chimera, Human, hFc Tag at 5 μg/ml(100 μl/well) on the plate. Dose response curve for Biotinylated Anti-SLPI Antibody, hFc Tag with the EC50 of 0.33 μg/ml determined by ELISA. »

SLPI HFc Chimera, Human

The purity of SLPI hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »

SLPI HFc Chimera, Human

SLPI hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background Elafin and SLPI (secretory leucocyte protease inhibitor) have multiple important roles both in normal homoeostasis and at sites of inflammation. These include antiprotease and antimicrobial activity as well as modulation of the response to LPS (lipopolysaccharide) stimulation. Elafin and SLPI are members of larger families of proteins secreted predominantly at mucosal sites, and have been shown to be modulated in multiple pathological conditions.
Synonyms ALP; BLPI; HUSI-1; MPI; WAP4; WFDC4; ALK1; HUSI; SLPI
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.